Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe
American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)
DOI: 10.1200/edbk-26-517652 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Mehak Trikha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have redefined the therapeutic landscape of oncology, producing durable responses across multiple tumor types and treatment settings. However, widespread adoption of ICIs has introduced challenges related to cost, optimal dosing, treatment duration, and immune-related toxicities, particularly in low- and middle-income countries (LMICs), where resource constraints have driven pragmatic innovations in delivery. This review summarizes exposure optimization strategies, including low-dose regimens, extended-interval dosing, fixed-duration therapy, and biomarker-guided patient selection supported by pharmacokinetic and pharmacodynamic data showing near-maximal PD-1 receptor occupancy at lower doses. Clinical evidence from randomized trials and real-world studies across tumor types suggest that these approaches may preserve efficacy in selected settings while improving affordability and feasibility. These LMIC-driven adaptations in treatment delivery, toxicity surveillance, and health-system design offer practical insights that may be applicable to high-resource settings facing sustainability challenges. Importantly, exposure optimization strategies have direct implications for toxicity burden, particularly immune-related adverse events (irAEs), hence the manuscript also reviews key organ-specific irAEs, with a focus on cardiovascular and gastrointestinal toxicities, emphasizing early detection, multidisciplinary management, and the relationship between treatment intensity and toxicity burden. Together, these approaches represent an attempt to improve the scalability of immunotherapy while balancing effectiveness, safety, and cost across different health care settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
- Department of Medicine, University of Rochester, Rochester, NY.
- Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Princess Margaret Cancer Center, Toronto, ON, Canada.
- Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Muzaffarpur, India.
ORCID-Profile: Vanita Noronha
Zitieren
APA
Trikha, M., Dent, S., Ludford, K., Ronan, K., Thomas, S., Grandhi, N., Prabhash, K., & Noronha, V. (2026). Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-517652
Vancouver
Trikha M, Dent S, Ludford K, Ronan K, Thomas S, Grandhi N, et al. Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-517652
BibTeX
@article{Trikha2026,
author = {Trikha, Mehak and Dent, Susan and Ludford, Kaysia and Ronan, Karine and Thomas, Sabu and Grandhi, Nikhil and Prabhash, Kumar and Noronha, Vanita},
title = {Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
volume = {46},
number = {3},
doi = {10.1200/edbk-26-517652}
}
EUVIMED